Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Who reported it (8)
- Definium Shares Rise on Successful Psychedelic Drug Trial WSJ · 5d ago
- Definium says LSD-based pill reduces anxiety in late-stage study Reuters · 5d ago
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder Yahoo Finance · 5d ago
- Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial STAT · 5d ago
- All eyes on psychedelic drugmakers as Definium, Compass near major catalysts BioSpace · 5d ago
- Definium’s LSD drug clears bar in first of two Phase 3 anxiety disorder trials Endpoints News · 5d ago
- DFTX Stock On Track For Worst Day In 9 Months As Investors Brace For Anxiety Trial Data Yahoo Finance · 5d ago
- Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety Fierce Biotech · 5d ago broke it first
Related trends
Credit card issuer Synchrony partners with OpenAI for ChatGPT shopping
Credit card issuer Synchrony has partnered with OpenAI to bring store cards and shopping offers into ChatGPT.
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
China's recovery sputters as consumption, output lose steam
China's economic recovery is losing momentum as retail sales, output, and investment slow down.
Alibaba to Sell Videogame Business for at Least $1.5 Billion
Alibaba moves to sell its videogame business to prioritize artificial intelligence and e-commerce.
Big investors hunt for tomorrow's AI winners as capex angst fades
Major investors are shifting focus toward emerging artificial intelligence opportunities as capital expenditure concerns diminish.
Private credit under strain as troubled loans swell
Private credit faces high stress levels and troubled loans, while industry leaders debate systemic risks.